Non-Hodgkin Lymphoma | Tumor

CURE’s non-Hodgkin lymphoma (NHL) page is an extensive resource of cancer information featuring the latest NHL news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on non-Hodgkin lymphoma.

New CAR-T Cell Therapy, Given with Keytruda, Is Safe and Effective in Treating Diffuse Large B Cell Lymphoma

October 13th 2020, 1:00pm

Article

Combining the immunotherapy Keytruda with a CAR-T cell therapy that targets the proteins CD19 and CD22 generates complete responses with minimal side effects, results from an early study demonstrate.

What Certain Patients with DLBCL Need To Know About Monjuvi-Revlimid

September 14th 2020, 3:00pm

Video

Patients with relapsed/refractory diffuse large B-cell lymphoma who are unable to undergo autologous stem cell transplant have a new treatment option in the combination of Monjuvi and Revlimid. The lead researcher on the study that led to the combination’s approval discusses what patients need to know.

Monjuvi-Revlimid Combination Approval Fills Unmet Need for Certain Patients with DLBCL

September 4th 2020, 6:00pm

Article

A recent approval of the combination of Monjuvi and Revlimid fills an unmet need for certain patients with DLBCL, according to Dr. Gilles Salles.

Intensifying Rituxan for Diffuse Large B-Cell Lymphoma Treatment Does Not Improve Health Outcomes

September 2nd 2020, 9:00pm

Article

Heightening the dose of the targeted drug Rituxan (rituximab) during the first four cycles of the R-CHOP regimen does not improve outcomes in treating patients with diffuse large B-cell lymphoma, the phase 3 HOVON-84 trial found.

Enzastaurin May Show Benefit in Subgroup of Patients with Diffuse Large B-Cell Lymphoma

August 25th 2020, 9:00pm

Article

The agent, in combination with the current standard of care, is being evaluated as a frontline treatment for patients with high-risk Denovo Genomic Marker 1 (DGM1)–positive DLBCL.

FDA Approves Monjuvi-Revlimid Combo for Relapsed/Refractory DLBCL

August 1st 2020, 5:24am

Article

The Food and Drug Administration approved Monjuvi in combination with Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

CURE's Top 5 Stories: July 2019

August 1st 2019, 8:00pm

Article

Here are the top 5 CURE stories for July 2019.

What Being a Survivor Means to 'The Pink Hulk', a Three-Time Cancer Survivor

July 29th 2019, 10:48pm

Video

Three-time cancer survivor and one-woman show writer and performer, Valerie David, sat down with CURE® to discuss life as a survivor.

Blending the Truth With Compassion in Cancer Care

July 27th 2019, 4:00pm

Article

This essay describes my journey with non-Hodgkin lymphoma — peripheral T-cell, not otherwise specified — and my most extraordinary nurse, Xuan Arnette, RN, OCN.

Friday Frontline: Cancer Updates, Research and Education on July 26, 2019

July 26th 2019, 8:49pm

Article

From landmark Senate legislation to the Pink Lemonade Stand Challenge, here’s what is making headlines in the cancer space this week.